Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 244 | 2024 | 6233 | 14.500 |
Why?
|
Anti-Asthmatic Agents | 57 | 2024 | 574 | 10.170 |
Why?
|
Bronchodilator Agents | 36 | 2024 | 512 | 4.730 |
Why?
|
Adrenal Cortex Hormones | 65 | 2024 | 1879 | 4.400 |
Why?
|
Albuterol | 25 | 2024 | 213 | 2.770 |
Why?
|
Administration, Inhalation | 60 | 2024 | 1156 | 2.190 |
Why?
|
Eosinophils | 30 | 2024 | 953 | 1.910 |
Why?
|
Glucocorticoids | 19 | 2023 | 2160 | 1.870 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 8 | 2019 | 111 | 1.770 |
Why?
|
Beclomethasone | 16 | 2022 | 38 | 1.720 |
Why?
|
Adrenergic beta-Agonists | 15 | 2018 | 346 | 1.720 |
Why?
|
Forced Expiratory Volume | 41 | 2023 | 1814 | 1.410 |
Why?
|
Receptors, Adrenergic, beta-2 | 9 | 2019 | 217 | 1.390 |
Why?
|
Sputum | 18 | 2024 | 506 | 1.380 |
Why?
|
Biological Products | 4 | 2024 | 912 | 1.360 |
Why?
|
Bronchi | 13 | 2021 | 846 | 1.300 |
Why?
|
Breath Tests | 12 | 2023 | 299 | 1.270 |
Why?
|
Nebulizers and Vaporizers | 6 | 2024 | 139 | 1.260 |
Why?
|
Budesonide | 10 | 2024 | 157 | 1.170 |
Why?
|
Leukotriene Antagonists | 10 | 2016 | 124 | 1.130 |
Why?
|
Pharmacogenetics | 7 | 2012 | 675 | 1.120 |
Why?
|
Interleukin-5 | 5 | 2024 | 269 | 1.010 |
Why?
|
Pulmonary Eosinophilia | 2 | 2021 | 78 | 0.920 |
Why?
|
Adrenergic beta-Antagonists | 4 | 2019 | 1241 | 0.860 |
Why?
|
Exhalation | 4 | 2013 | 181 | 0.830 |
Why?
|
Acetates | 6 | 2018 | 321 | 0.830 |
Why?
|
Asthma, Exercise-Induced | 3 | 2013 | 23 | 0.790 |
Why?
|
Propranolol | 2 | 2014 | 490 | 0.780 |
Why?
|
Adult | 167 | 2024 | 220969 | 0.780 |
Why?
|
Lung | 27 | 2024 | 9998 | 0.770 |
Why?
|
Mucus | 5 | 2024 | 342 | 0.750 |
Why?
|
Respiratory Sounds | 3 | 2021 | 702 | 0.740 |
Why?
|
Eosinophilia | 8 | 2024 | 559 | 0.720 |
Why?
|
Respiratory Function Tests | 20 | 2024 | 1683 | 0.710 |
Why?
|
Interleukin-13 | 5 | 2024 | 392 | 0.710 |
Why?
|
Respiratory Mechanics | 3 | 2015 | 699 | 0.680 |
Why?
|
Humans | 268 | 2024 | 760617 | 0.680 |
Why?
|
Respiratory Mucosa | 7 | 2024 | 438 | 0.670 |
Why?
|
Mast Cells | 6 | 2018 | 1392 | 0.670 |
Why?
|
Double-Blind Method | 39 | 2024 | 12334 | 0.660 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 11 | 2022 | 3204 | 0.650 |
Why?
|
Lipoxins | 6 | 2014 | 419 | 0.650 |
Why?
|
Asthma, Aspirin-Induced | 5 | 2023 | 202 | 0.630 |
Why?
|
Severity of Illness Index | 36 | 2021 | 15828 | 0.630 |
Why?
|
Nitric Oxide | 13 | 2023 | 2135 | 0.620 |
Why?
|
Disease Progression | 19 | 2024 | 13495 | 0.610 |
Why?
|
Quinolines | 5 | 2018 | 764 | 0.590 |
Why?
|
Scopolamine Derivatives | 5 | 2015 | 24 | 0.550 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2017 | 355 | 0.530 |
Why?
|
Receptors, Leukotriene | 3 | 2019 | 95 | 0.520 |
Why?
|
Middle Aged | 115 | 2024 | 220584 | 0.500 |
Why?
|
Metered Dose Inhalers | 5 | 2023 | 25 | 0.500 |
Why?
|
Ankyrin Repeat | 1 | 2015 | 19 | 0.500 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 823 | 0.500 |
Why?
|
Male | 161 | 2024 | 360358 | 0.490 |
Why?
|
Bronchoconstriction | 4 | 2010 | 142 | 0.480 |
Why?
|
Antibodies, Monoclonal | 10 | 2024 | 9172 | 0.480 |
Why?
|
Leukotriene B4 | 2 | 2013 | 280 | 0.480 |
Why?
|
Polymorphism, Single Nucleotide | 19 | 2022 | 15908 | 0.470 |
Why?
|
Drug Combinations | 6 | 2024 | 2048 | 0.460 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 178 | 0.460 |
Why?
|
Immunoglobulin E | 12 | 2024 | 1502 | 0.460 |
Why?
|
Female | 162 | 2024 | 392148 | 0.460 |
Why?
|
Drug Therapy, Combination | 15 | 2023 | 6305 | 0.450 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2015 | 313 | 0.450 |
Why?
|
Androstadienes | 9 | 2015 | 348 | 0.450 |
Why?
|
Particle Size | 9 | 2018 | 1648 | 0.450 |
Why?
|
Hypersensitivity, Immediate | 3 | 2023 | 347 | 0.420 |
Why?
|
Bronchial Hyperreactivity | 6 | 2017 | 302 | 0.420 |
Why?
|
Self Report | 4 | 2023 | 3723 | 0.410 |
Why?
|
Bronchial Provocation Tests | 6 | 2019 | 216 | 0.400 |
Why?
|
Phenotype | 25 | 2023 | 16571 | 0.400 |
Why?
|
Drug Tolerance | 1 | 2013 | 367 | 0.400 |
Why?
|
Airway Remodeling | 4 | 2021 | 133 | 0.380 |
Why?
|
Pharmacokinetics | 1 | 2011 | 86 | 0.380 |
Why?
|
Genome-Wide Association Study | 11 | 2023 | 12661 | 0.370 |
Why?
|
Quality of Life | 17 | 2024 | 13347 | 0.360 |
Why?
|
Spirometry | 7 | 2022 | 928 | 0.360 |
Why?
|
Pulmonary Medicine | 2 | 2013 | 221 | 0.350 |
Why?
|
Saline Solution, Hypertonic | 1 | 2010 | 114 | 0.350 |
Why?
|
Interleukin-6 | 5 | 2021 | 3206 | 0.350 |
Why?
|
Obesity | 13 | 2024 | 12933 | 0.340 |
Why?
|
Young Adult | 46 | 2024 | 59179 | 0.340 |
Why?
|
Child | 49 | 2024 | 80079 | 0.340 |
Why?
|
Medication Adherence | 3 | 2023 | 2174 | 0.340 |
Why?
|
Adolescent | 58 | 2024 | 88234 | 0.340 |
Why?
|
Patient Care Planning | 1 | 2015 | 905 | 0.340 |
Why?
|
Anti-Inflammatory Agents | 3 | 2017 | 1810 | 0.330 |
Why?
|
Eosinophil Peroxidase | 3 | 2024 | 21 | 0.330 |
Why?
|
Leukocyte Count | 10 | 2024 | 1597 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10199 | 0.310 |
Why?
|
Inflammation | 16 | 2024 | 10760 | 0.300 |
Why?
|
Alendronate | 2 | 2019 | 175 | 0.300 |
Why?
|
Morbidity | 5 | 2023 | 1750 | 0.290 |
Why?
|
Cysteine | 2 | 2018 | 891 | 0.290 |
Why?
|
Allergens | 7 | 2021 | 1429 | 0.280 |
Why?
|
Mucin 5AC | 2 | 2024 | 96 | 0.280 |
Why?
|
Cholecalciferol | 3 | 2018 | 553 | 0.280 |
Why?
|
Insulin Resistance | 2 | 2022 | 3954 | 0.280 |
Why?
|
Tryptases | 2 | 2018 | 176 | 0.280 |
Why?
|
Social Class | 3 | 2022 | 1992 | 0.270 |
Why?
|
Treatment Failure | 7 | 2021 | 2635 | 0.270 |
Why?
|
Epithelial Cells | 8 | 2024 | 3672 | 0.270 |
Why?
|
Genotype | 14 | 2020 | 12978 | 0.270 |
Why?
|
Bronchoalveolar Lavage Fluid | 8 | 2024 | 755 | 0.260 |
Why?
|
Patient Preference | 2 | 2023 | 925 | 0.250 |
Why?
|
Polymorphism, Genetic | 7 | 2024 | 4242 | 0.250 |
Why?
|
Cytokines | 8 | 2024 | 7373 | 0.250 |
Why?
|
Th2 Cells | 3 | 2020 | 1056 | 0.250 |
Why?
|
Cross-Over Studies | 12 | 2019 | 2079 | 0.240 |
Why?
|
Treatment Outcome | 36 | 2024 | 64568 | 0.240 |
Why?
|
Puerto Rico | 2 | 2023 | 378 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2019 | 10754 | 0.230 |
Why?
|
Leukotrienes | 3 | 2013 | 231 | 0.230 |
Why?
|
Cardiac Tamponade | 1 | 2005 | 173 | 0.230 |
Why?
|
Methacholine Chloride | 5 | 2019 | 220 | 0.230 |
Why?
|
Pulmonary Artery | 2 | 2019 | 1927 | 0.220 |
Why?
|
Vital Capacity | 6 | 2021 | 971 | 0.220 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2005 | 216 | 0.220 |
Why?
|
Deoxyribonuclease I | 1 | 2024 | 224 | 0.220 |
Why?
|
Aged | 44 | 2024 | 169042 | 0.220 |
Why?
|
Common Cold | 1 | 2023 | 63 | 0.220 |
Why?
|
Registries | 1 | 2019 | 8207 | 0.220 |
Why?
|
Bronchoscopy | 6 | 2024 | 909 | 0.210 |
Why?
|
Uteroglobin | 1 | 2023 | 56 | 0.210 |
Why?
|
Cohort Studies | 24 | 2021 | 41457 | 0.210 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 469 | 0.200 |
Why?
|
Sulfides | 5 | 2018 | 169 | 0.200 |
Why?
|
Cholinergic Antagonists | 2 | 2015 | 167 | 0.200 |
Why?
|
Chemokine CCL5 | 1 | 2023 | 214 | 0.200 |
Why?
|
RGS Proteins | 1 | 2022 | 74 | 0.200 |
Why?
|
Lectins | 1 | 2024 | 489 | 0.200 |
Why?
|
Triamcinolone Acetonide | 2 | 2003 | 100 | 0.200 |
Why?
|
Rodent Control | 1 | 2021 | 15 | 0.200 |
Why?
|
Triamcinolone | 3 | 2019 | 68 | 0.190 |
Why?
|
Cyclopropanes | 5 | 2018 | 432 | 0.190 |
Why?
|
Aged, 80 and over | 18 | 2024 | 58894 | 0.190 |
Why?
|
Inflammasomes | 2 | 2019 | 526 | 0.190 |
Why?
|
Aspirin | 5 | 2023 | 3127 | 0.190 |
Why?
|
Models, Genetic | 1 | 2011 | 3431 | 0.190 |
Why?
|
Muscarinic Antagonists | 1 | 2022 | 135 | 0.190 |
Why?
|
Respiratory System | 2 | 2018 | 563 | 0.190 |
Why?
|
Respiratory Hypersensitivity | 1 | 2023 | 274 | 0.180 |
Why?
|
Infusions, Parenteral | 1 | 2021 | 397 | 0.180 |
Why?
|
Penicillium chrysogenum | 1 | 2020 | 7 | 0.180 |
Why?
|
Docosahexaenoic Acids | 2 | 2023 | 907 | 0.180 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5672 | 0.180 |
Why?
|
Peak Expiratory Flow Rate | 6 | 2018 | 144 | 0.180 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2021 | 241 | 0.180 |
Why?
|
Prostaglandins | 3 | 2023 | 398 | 0.180 |
Why?
|
Progesterone Reductase | 1 | 2020 | 14 | 0.180 |
Why?
|
Steroid Isomerases | 1 | 2020 | 19 | 0.180 |
Why?
|
Sex Factors | 7 | 2021 | 10548 | 0.180 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 2 | 2018 | 76 | 0.170 |
Why?
|
Fish Oils | 1 | 2003 | 483 | 0.170 |
Why?
|
Respiratory Tract Infections | 2 | 2019 | 1009 | 0.170 |
Why?
|
Environmental Exposure | 5 | 2021 | 4483 | 0.170 |
Why?
|
Steroids | 1 | 2024 | 929 | 0.170 |
Why?
|
Air Pollution, Indoor | 2 | 2021 | 900 | 0.160 |
Why?
|
Research Design | 5 | 2021 | 6174 | 0.160 |
Why?
|
Granulocytes | 1 | 2021 | 551 | 0.160 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2022 | 450 | 0.160 |
Why?
|
Aspergillus fumigatus | 1 | 2020 | 157 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2020 | 418 | 0.160 |
Why?
|
Ipratropium | 1 | 2018 | 19 | 0.160 |
Why?
|
Moraxella | 1 | 2018 | 25 | 0.160 |
Why?
|
Behavior | 1 | 2021 | 540 | 0.150 |
Why?
|
Corynebacterium | 1 | 2018 | 48 | 0.150 |
Why?
|
Aerosols | 2 | 2018 | 635 | 0.150 |
Why?
|
Patient Selection | 2 | 2021 | 4237 | 0.150 |
Why?
|
Smoking | 6 | 2021 | 9050 | 0.150 |
Why?
|
Pregnenediones | 2 | 2016 | 29 | 0.150 |
Why?
|
Cell Count | 4 | 2017 | 1835 | 0.150 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7389 | 0.150 |
Why?
|
Prostaglandin D2 | 2 | 2015 | 108 | 0.150 |
Why?
|
Muscle Stretching Exercises | 1 | 2018 | 37 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 4 | 2023 | 3194 | 0.150 |
Why?
|
Coronavirus | 1 | 2020 | 156 | 0.150 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2018 | 115 | 0.150 |
Why?
|
Neutrophils | 6 | 2023 | 3763 | 0.150 |
Why?
|
Schools | 2 | 2021 | 1483 | 0.150 |
Why?
|
Serpins | 1 | 2019 | 247 | 0.150 |
Why?
|
Longitudinal Studies | 8 | 2023 | 14591 | 0.140 |
Why?
|
Inhalation Spacers | 1 | 2017 | 4 | 0.140 |
Why?
|
Sports | 1 | 2003 | 705 | 0.140 |
Why?
|
Mouth | 1 | 2020 | 381 | 0.140 |
Why?
|
Vitamin D Deficiency | 3 | 2018 | 1388 | 0.140 |
Why?
|
Drug Administration Schedule | 6 | 2015 | 4845 | 0.140 |
Why?
|
Sinusitis | 3 | 2023 | 991 | 0.140 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3607 | 0.140 |
Why?
|
Arginine | 2 | 2012 | 933 | 0.140 |
Why?
|
Databases, Factual | 4 | 2016 | 7960 | 0.140 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2017 | 274 | 0.140 |
Why?
|
Multienzyme Complexes | 1 | 2020 | 666 | 0.130 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2812 | 0.130 |
Why?
|
Age of Onset | 6 | 2014 | 3302 | 0.130 |
Why?
|
United States | 18 | 2023 | 72272 | 0.130 |
Why?
|
Waist Circumference | 2 | 2018 | 933 | 0.130 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2018 | 284 | 0.130 |
Why?
|
Airway Obstruction | 2 | 2018 | 661 | 0.130 |
Why?
|
Interleukins | 2 | 2017 | 783 | 0.130 |
Why?
|
Disease Management | 3 | 2023 | 2506 | 0.130 |
Why?
|
Resistance Training | 1 | 2018 | 193 | 0.130 |
Why?
|
Lymphocytes | 2 | 2013 | 2604 | 0.120 |
Why?
|
Environment | 1 | 2021 | 1123 | 0.120 |
Why?
|
Plasma | 1 | 2018 | 586 | 0.120 |
Why?
|
Tosyl Compounds | 2 | 2005 | 115 | 0.120 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1079 | 0.120 |
Why?
|
Ibuprofen | 1 | 2016 | 229 | 0.120 |
Why?
|
RNA, Messenger | 5 | 2023 | 12758 | 0.120 |
Why?
|
Airway Resistance | 2 | 2007 | 406 | 0.120 |
Why?
|
Drug Resistance | 2 | 2020 | 1594 | 0.120 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2019 | 574 | 0.120 |
Why?
|
Forced Expiratory Flow Rates | 3 | 2015 | 75 | 0.120 |
Why?
|
Azithromycin | 1 | 2015 | 199 | 0.120 |
Why?
|
Thromboplastin | 1 | 2016 | 286 | 0.120 |
Why?
|
Cell Shape | 1 | 2015 | 369 | 0.110 |
Why?
|
Echium | 1 | 2013 | 3 | 0.110 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 702 | 0.110 |
Why?
|
Child, Preschool | 15 | 2022 | 42188 | 0.110 |
Why?
|
gamma-Linolenic Acid | 1 | 2013 | 16 | 0.110 |
Why?
|
Epoxide Hydrolases | 1 | 2014 | 122 | 0.110 |
Why?
|
Gastroesophageal Reflux | 2 | 2011 | 821 | 0.110 |
Why?
|
Biomedical Research | 4 | 2013 | 3426 | 0.110 |
Why?
|
Drug Hypersensitivity | 2 | 2019 | 917 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1202 | 0.110 |
Why?
|
Prospective Studies | 13 | 2023 | 54360 | 0.110 |
Why?
|
Integrin beta Chains | 1 | 2013 | 115 | 0.110 |
Why?
|
Kv Channel-Interacting Proteins | 1 | 2013 | 40 | 0.110 |
Why?
|
Dietary Supplements | 2 | 2018 | 3411 | 0.110 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2019 | 1875 | 0.110 |
Why?
|
Hypertriglyceridemia | 1 | 2016 | 293 | 0.110 |
Why?
|
Genetic Markers | 2 | 2013 | 2601 | 0.100 |
Why?
|
Dendritic Cells | 3 | 2016 | 2722 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3492 | 0.100 |
Why?
|
Cystic Fibrosis | 1 | 2022 | 1285 | 0.100 |
Why?
|
Plant Oils | 1 | 2013 | 198 | 0.100 |
Why?
|
Lung Volume Measurements | 3 | 2019 | 375 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1113 | 0.100 |
Why?
|
Clinical Competence | 1 | 2008 | 4789 | 0.100 |
Why?
|
Socioeconomic Factors | 3 | 2022 | 7798 | 0.100 |
Why?
|
Pneumonia | 3 | 2017 | 2143 | 0.100 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2012 | 85 | 0.100 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2013 | 163 | 0.100 |
Why?
|
Acetaminophen | 1 | 2016 | 555 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 796 | 0.100 |
Why?
|
Immunity, Cellular | 1 | 2018 | 1550 | 0.100 |
Why?
|
Pilot Projects | 4 | 2020 | 8618 | 0.100 |
Why?
|
Hospitalization | 5 | 2021 | 10704 | 0.100 |
Why?
|
Microspheres | 1 | 2015 | 782 | 0.100 |
Why?
|
Fetal Proteins | 1 | 2012 | 98 | 0.100 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2014 | 201 | 0.100 |
Why?
|
Lung Diseases | 1 | 2022 | 1909 | 0.100 |
Why?
|
ADAM Proteins | 1 | 2013 | 238 | 0.100 |
Why?
|
Aorta | 1 | 2019 | 2041 | 0.100 |
Why?
|
Sleep | 2 | 2021 | 4758 | 0.090 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 962 | 0.090 |
Why?
|
Guidelines as Topic | 2 | 2018 | 1386 | 0.090 |
Why?
|
Menstruation | 1 | 2013 | 306 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2012 | 17878 | 0.090 |
Why?
|
Thrombosis | 1 | 2005 | 2943 | 0.090 |
Why?
|
Peptidylprolyl Isomerase | 1 | 2011 | 97 | 0.090 |
Why?
|
Case-Control Studies | 11 | 2021 | 22148 | 0.090 |
Why?
|
Gene Frequency | 3 | 2015 | 3601 | 0.090 |
Why?
|
Logistic Models | 9 | 2019 | 13245 | 0.090 |
Why?
|
Carrier Proteins | 3 | 2014 | 4935 | 0.090 |
Why?
|
Macrolides | 1 | 2012 | 204 | 0.090 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2012 | 367 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 6 | 2024 | 20556 | 0.090 |
Why?
|
Pandemics | 2 | 2022 | 8645 | 0.090 |
Why?
|
Muscle, Smooth | 1 | 2015 | 927 | 0.090 |
Why?
|
Immunization | 2 | 2018 | 1217 | 0.090 |
Why?
|
Cross-Sectional Studies | 10 | 2023 | 26049 | 0.090 |
Why?
|
Body Mass Index | 6 | 2024 | 12943 | 0.090 |
Why?
|
Single-Blind Method | 3 | 2021 | 1575 | 0.090 |
Why?
|
Epithelium | 1 | 2015 | 1603 | 0.090 |
Why?
|
Nitrogen Oxides | 1 | 2010 | 129 | 0.090 |
Why?
|
Clarithromycin | 1 | 2010 | 86 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2017 | 1528 | 0.090 |
Why?
|
Age Factors | 9 | 2018 | 18381 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2021 | 2569 | 0.090 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 708 | 0.090 |
Why?
|
Injections, Subcutaneous | 2 | 2021 | 671 | 0.090 |
Why?
|
Churg-Strauss Syndrome | 1 | 2010 | 75 | 0.080 |
Why?
|
Comorbidity | 4 | 2020 | 10505 | 0.080 |
Why?
|
5' Untranslated Regions | 1 | 2011 | 253 | 0.080 |
Why?
|
Bronchoalveolar Lavage | 2 | 2024 | 129 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 2270 | 0.080 |
Why?
|
T-Box Domain Proteins | 1 | 2012 | 469 | 0.080 |
Why?
|
Interferon-beta | 1 | 2011 | 345 | 0.080 |
Why?
|
Bone Density | 2 | 2003 | 3548 | 0.080 |
Why?
|
Placebos | 2 | 2011 | 1667 | 0.080 |
Why?
|
Secondary Prevention | 1 | 2015 | 1469 | 0.080 |
Why?
|
Arachidonic Acid | 1 | 2010 | 427 | 0.080 |
Why?
|
Chemokines | 2 | 2024 | 954 | 0.080 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2010 | 2495 | 0.080 |
Why?
|
Exercise Test | 2 | 2013 | 2127 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2014 | 1169 | 0.080 |
Why?
|
Electrocoagulation | 1 | 2009 | 152 | 0.080 |
Why?
|
Ethanolamines | 2 | 2022 | 153 | 0.080 |
Why?
|
Risk Factors | 9 | 2021 | 74115 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2020 | 5239 | 0.080 |
Why?
|
Nutrition Surveys | 1 | 2016 | 1723 | 0.080 |
Why?
|
Mice | 14 | 2023 | 81368 | 0.080 |
Why?
|
Skin Tests | 5 | 2010 | 637 | 0.080 |
Why?
|
Stress, Physiological | 1 | 2016 | 1403 | 0.080 |
Why?
|
Income | 1 | 2017 | 1870 | 0.080 |
Why?
|
Bronchoconstrictor Agents | 3 | 2019 | 77 | 0.080 |
Why?
|
Arginase | 1 | 2008 | 78 | 0.080 |
Why?
|
Genetic Variation | 6 | 2021 | 6561 | 0.080 |
Why?
|
Receptors, Lipoxin | 1 | 2008 | 83 | 0.080 |
Why?
|
Respiratory Tract Diseases | 1 | 2013 | 750 | 0.070 |
Why?
|
Th1 Cells | 1 | 2013 | 1027 | 0.070 |
Why?
|
Toll-Like Receptors | 1 | 2011 | 575 | 0.070 |
Why?
|
Receptors, Formyl Peptide | 1 | 2008 | 146 | 0.070 |
Why?
|
Macrophages, Alveolar | 1 | 2010 | 411 | 0.070 |
Why?
|
Interleukin-17 | 1 | 2013 | 911 | 0.070 |
Why?
|
Hyperglycemia | 1 | 2016 | 1375 | 0.070 |
Why?
|
Multiprotein Complexes | 1 | 2014 | 1118 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4803 | 0.070 |
Why?
|
Heart Ventricles | 1 | 2019 | 3796 | 0.070 |
Why?
|
Placebo Effect | 1 | 2011 | 518 | 0.070 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 730 | 0.070 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2016 | 1080 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2222 | 0.070 |
Why?
|
Prevalence | 5 | 2016 | 15689 | 0.070 |
Why?
|
Acupuncture Therapy | 1 | 2011 | 486 | 0.070 |
Why?
|
Nasal Polyps | 3 | 2018 | 395 | 0.070 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 1 | 2006 | 57 | 0.070 |
Why?
|
Anti-Bacterial Agents | 3 | 2015 | 7402 | 0.070 |
Why?
|
Estradiol | 1 | 2014 | 1937 | 0.070 |
Why?
|
Gene Expression | 5 | 2021 | 7568 | 0.070 |
Why?
|
Membrane Proteins | 3 | 2013 | 7847 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6338 | 0.070 |
Why?
|
Quantitative Trait Loci | 3 | 2021 | 2112 | 0.070 |
Why?
|
Specimen Handling | 1 | 2010 | 701 | 0.060 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1335 | 0.060 |
Why?
|
Telemedicine | 1 | 2023 | 3050 | 0.060 |
Why?
|
Natural Killer T-Cells | 1 | 2009 | 322 | 0.060 |
Why?
|
Prednisone | 2 | 2012 | 1562 | 0.060 |
Why?
|
Vitamins | 1 | 2014 | 1635 | 0.060 |
Why?
|
Internet | 1 | 2017 | 3090 | 0.060 |
Why?
|
DNA | 1 | 2019 | 7196 | 0.060 |
Why?
|
Tobacco Smoke Pollution | 1 | 2011 | 819 | 0.060 |
Why?
|
Administration, Oral | 4 | 2018 | 4010 | 0.060 |
Why?
|
Receptors, Adrenergic, beta | 1 | 2005 | 242 | 0.060 |
Why?
|
Lactoperoxidase | 1 | 2024 | 5 | 0.060 |
Why?
|
Animals | 16 | 2023 | 168201 | 0.060 |
Why?
|
Polysomnography | 1 | 2011 | 1849 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 2057 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1890 | 0.060 |
Why?
|
Acute Disease | 4 | 2019 | 7237 | 0.060 |
Why?
|
Family Practice | 1 | 2007 | 507 | 0.060 |
Why?
|
Retrospective Studies | 12 | 2023 | 80566 | 0.060 |
Why?
|
Catheter Ablation | 1 | 2017 | 2634 | 0.060 |
Why?
|
Phospholipases A | 1 | 2005 | 204 | 0.060 |
Why?
|
Poverty | 1 | 2016 | 2692 | 0.060 |
Why?
|
Antigens, Dermatophagoides | 2 | 2018 | 98 | 0.060 |
Why?
|
Cells, Cultured | 5 | 2019 | 18937 | 0.060 |
Why?
|
Housing | 1 | 2009 | 669 | 0.060 |
Why?
|
Hypersensitivity | 2 | 2010 | 1167 | 0.060 |
Why?
|
Proteomics | 2 | 2024 | 3836 | 0.060 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2004 | 89 | 0.060 |
Why?
|
Receptors, Thromboxane | 1 | 2023 | 30 | 0.050 |
Why?
|
Thromboxanes | 1 | 2023 | 45 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2014 | 3113 | 0.050 |
Why?
|
Receptor, Cholecystokinin A | 1 | 2023 | 13 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2018 | 1033 | 0.050 |
Why?
|
Leukotriene E4 | 1 | 2023 | 75 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2011 | 1086 | 0.050 |
Why?
|
Clinical Trials as Topic | 3 | 2015 | 7995 | 0.050 |
Why?
|
Gels | 1 | 2024 | 420 | 0.050 |
Why?
|
Interferon-gamma | 2 | 2016 | 3145 | 0.050 |
Why?
|
Deoxyribonucleases | 1 | 2024 | 211 | 0.050 |
Why?
|
Dexamethasone | 1 | 2010 | 1947 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20074 | 0.050 |
Why?
|
Leukotriene C4 | 1 | 2003 | 79 | 0.050 |
Why?
|
Indoles | 3 | 2005 | 1830 | 0.050 |
Why?
|
Cholecystokinin | 1 | 2023 | 115 | 0.050 |
Why?
|
Antigens, CD | 1 | 2013 | 3998 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Mucin-5B | 1 | 2023 | 148 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2003 | 128 | 0.050 |
Why?
|
Occupational Diseases | 1 | 2010 | 1490 | 0.050 |
Why?
|
Fluocinolone Acetonide | 1 | 2002 | 38 | 0.050 |
Why?
|
Signal Transduction | 5 | 2020 | 23416 | 0.050 |
Why?
|
Periodicals as Topic | 1 | 2013 | 1463 | 0.050 |
Why?
|
Mice, Obese | 1 | 2023 | 418 | 0.050 |
Why?
|
Rodenticides | 1 | 2021 | 21 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2016 | 6474 | 0.050 |
Why?
|
Receptors, Interleukin-4 | 1 | 2021 | 64 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2021 | 1437 | 0.050 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2024 | 592 | 0.050 |
Why?
|
Interleukin-2 | 1 | 2008 | 1887 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5491 | 0.050 |
Why?
|
Africa | 1 | 2023 | 710 | 0.050 |
Why?
|
Inflammation Mediators | 1 | 2010 | 1884 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2024 | 39063 | 0.050 |
Why?
|
Eicosanoids | 1 | 2023 | 282 | 0.050 |
Why?
|
Glucuronidase | 1 | 2022 | 202 | 0.050 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5780 | 0.050 |
Why?
|
Mucins | 1 | 2024 | 568 | 0.050 |
Why?
|
Nasal Mucosa | 1 | 2024 | 415 | 0.050 |
Why?
|
Odds Ratio | 4 | 2015 | 9643 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12043 | 0.040 |
Why?
|
Eosinophil-Derived Neurotoxin | 1 | 2020 | 13 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4570 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2015 | 4174 | 0.040 |
Why?
|
Fatal Outcome | 1 | 2005 | 1835 | 0.040 |
Why?
|
Histamine | 1 | 2022 | 499 | 0.040 |
Why?
|
Hypertension | 2 | 2020 | 8529 | 0.040 |
Why?
|
Alleles | 3 | 2020 | 6861 | 0.040 |
Why?
|
Dinoprostone | 1 | 2023 | 597 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2011 | 3688 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 2238 | 0.040 |
Why?
|
Proteins | 2 | 2012 | 6030 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11874 | 0.040 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2021 | 517 | 0.040 |
Why?
|
Health Care Costs | 1 | 2013 | 3238 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2002 | 957 | 0.040 |
Why?
|
Immunoblotting | 2 | 2014 | 1646 | 0.040 |
Why?
|
Pelvic Bones | 1 | 2001 | 270 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Mice, Knockout | 4 | 2018 | 14389 | 0.040 |
Why?
|
Geography | 1 | 2021 | 652 | 0.040 |
Why?
|
ROC Curve | 2 | 2005 | 3575 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2019 | 2700 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2010 | 3039 | 0.040 |
Why?
|
Cats | 2 | 2010 | 975 | 0.040 |
Why?
|
Glucosephosphate Dehydrogenase | 1 | 2019 | 208 | 0.040 |
Why?
|
Flow Cytometry | 3 | 2014 | 5863 | 0.040 |
Why?
|
Infant | 5 | 2022 | 36152 | 0.040 |
Why?
|
Physical Stimulation | 1 | 2019 | 517 | 0.040 |
Why?
|
Advisory Committees | 1 | 2021 | 787 | 0.040 |
Why?
|
Oxidants | 1 | 2018 | 169 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 322 | 0.040 |
Why?
|
Premenopause | 1 | 2001 | 1038 | 0.040 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 131 | 0.040 |
Why?
|
Disease Susceptibility | 2 | 2017 | 1788 | 0.040 |
Why?
|
Age Distribution | 2 | 2015 | 2871 | 0.030 |
Why?
|
Linkage Disequilibrium | 2 | 2012 | 1994 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2008 | 4533 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 2018 | 301 | 0.030 |
Why?
|
Prostaglandins D | 1 | 2015 | 27 | 0.030 |
Why?
|
Aging | 1 | 2015 | 8699 | 0.030 |
Why?
|
Growth | 1 | 2018 | 365 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2019 | 696 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9604 | 0.030 |
Why?
|
Elasticity | 1 | 2018 | 655 | 0.030 |
Why?
|
Phenylcarbamates | 2 | 2005 | 38 | 0.030 |
Why?
|
Air Pollutants | 1 | 2010 | 2893 | 0.030 |
Why?
|
Research Personnel | 1 | 2020 | 588 | 0.030 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 7871 | 0.030 |
Why?
|
Mouth Mucosa | 1 | 2018 | 432 | 0.030 |
Why?
|
Headache | 1 | 2023 | 1255 | 0.030 |
Why?
|
Demography | 1 | 2020 | 1643 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3800 | 0.030 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 474 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6224 | 0.030 |
Why?
|
Femur | 1 | 2001 | 1307 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2015 | 117 | 0.030 |
Why?
|
RNA, Bacterial | 1 | 2016 | 393 | 0.030 |
Why?
|
Puberty | 1 | 2018 | 501 | 0.030 |
Why?
|
Linear Models | 2 | 2018 | 5866 | 0.030 |
Why?
|
Nose | 1 | 2018 | 521 | 0.030 |
Why?
|
Immunotherapy | 1 | 2010 | 4642 | 0.030 |
Why?
|
Dogs | 2 | 2010 | 3838 | 0.030 |
Why?
|
Organ Size | 1 | 2019 | 2252 | 0.030 |
Why?
|
Ovalbumin | 1 | 2016 | 675 | 0.030 |
Why?
|
Prognosis | 4 | 2021 | 29600 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2016 | 4341 | 0.030 |
Why?
|
8,11,14-Eicosatrienoic Acid | 1 | 2013 | 64 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1700 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2017 | 2261 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8426 | 0.030 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2013 | 22 | 0.030 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2013 | 38 | 0.030 |
Why?
|
STAT4 Transcription Factor | 1 | 2013 | 93 | 0.030 |
Why?
|
Seeds | 1 | 2013 | 122 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 2 | 2013 | 1835 | 0.030 |
Why?
|
alpha-Linolenic Acid | 1 | 2013 | 144 | 0.030 |
Why?
|
Smoking Cessation | 2 | 2015 | 2056 | 0.030 |
Why?
|
Adiposity | 1 | 2023 | 1879 | 0.030 |
Why?
|
Delivery of Health Care | 3 | 2020 | 5332 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3419 | 0.030 |
Why?
|
Naphthyridines | 1 | 2014 | 143 | 0.030 |
Why?
|
Bone and Bones | 1 | 2003 | 2565 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2014 | 0.030 |
Why?
|
Nuclear Pore | 1 | 2012 | 62 | 0.030 |
Why?
|
Androgens | 1 | 2020 | 1285 | 0.030 |
Why?
|
Hydrogels | 1 | 2018 | 720 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 2001 | 1874 | 0.020 |
Why?
|
Workflow | 1 | 2017 | 849 | 0.020 |
Why?
|
Homeostasis | 1 | 2023 | 3321 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12116 | 0.020 |
Why?
|
Exons | 1 | 2018 | 2381 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2278 | 0.020 |
Why?
|
Blotting, Western | 1 | 2019 | 5034 | 0.020 |
Why?
|
Interferon Regulatory Factor-1 | 1 | 2011 | 68 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 161 | 0.020 |
Why?
|
Netherlands | 1 | 2016 | 2221 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2014 | 596 | 0.020 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 1587 | 0.020 |
Why?
|
Cardiovascular Diseases | 2 | 2021 | 15498 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15251 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2022 | 4739 | 0.020 |
Why?
|
Shoulder Joint | 1 | 2018 | 742 | 0.020 |
Why?
|
Societies, Medical | 1 | 2023 | 3900 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2241 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2734 | 0.020 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 43 | 0.020 |
Why?
|
Chlamydophila pneumoniae | 1 | 2010 | 53 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3410 | 0.020 |
Why?
|
Turkey | 1 | 2011 | 253 | 0.020 |
Why?
|
Interleukin-12 | 1 | 2013 | 577 | 0.020 |
Why?
|
Down-Regulation | 2 | 2010 | 2915 | 0.020 |
Why?
|
Thrombospondins | 1 | 2011 | 193 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2013 | 540 | 0.020 |
Why?
|
Equipment Design | 1 | 2018 | 3501 | 0.020 |
Why?
|
Mites | 1 | 2010 | 46 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2015 | 1674 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2013 | 22115 | 0.020 |
Why?
|
Hospital Costs | 1 | 2016 | 947 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 39913 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6074 | 0.020 |
Why?
|
Pollen | 1 | 2010 | 80 | 0.020 |
Why?
|
Eicosapentaenoic Acid | 1 | 2013 | 561 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1661 | 0.020 |
Why?
|
Discriminant Analysis | 1 | 2009 | 223 | 0.020 |
Why?
|
Diagnostic Self Evaluation | 1 | 2011 | 224 | 0.020 |
Why?
|
Bibliometrics | 1 | 2013 | 352 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1608 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 2467 | 0.020 |
Why?
|
Cockroaches | 1 | 2009 | 97 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1618 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4269 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2015 | 3088 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2625 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 2011 | 593 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2011 | 656 | 0.020 |
Why?
|
Editorial Policies | 1 | 2013 | 458 | 0.020 |
Why?
|
Risk Assessment | 3 | 2018 | 23972 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 1048 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2016 | 1963 | 0.020 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2011 | 277 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2012 | 699 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2014 | 10432 | 0.020 |
Why?
|
Rhinitis | 1 | 2015 | 747 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2013 | 998 | 0.020 |
Why?
|
Models, Biological | 2 | 2015 | 9461 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1970 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4947 | 0.020 |
Why?
|
Biological Availability | 1 | 2008 | 389 | 0.020 |
Why?
|
Hydroxyeicosatetraenoic Acids | 1 | 2008 | 224 | 0.020 |
Why?
|
London | 1 | 2007 | 233 | 0.020 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 306 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1703 | 0.020 |
Why?
|
Body Height | 1 | 2013 | 1565 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 14648 | 0.020 |
Why?
|
Monocytes | 1 | 2016 | 2565 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2018 | 18221 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2011 | 724 | 0.020 |
Why?
|
Receptors, Notch | 1 | 2011 | 743 | 0.020 |
Why?
|
Vasculitis | 1 | 2010 | 522 | 0.020 |
Why?
|
Dust | 1 | 2009 | 487 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2010 | 616 | 0.020 |
Why?
|
Phytohemagglutinins | 1 | 2005 | 165 | 0.020 |
Why?
|
Bacteria | 1 | 2016 | 2192 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 1865 | 0.020 |
Why?
|
Sulfonamides | 2 | 2005 | 1977 | 0.020 |
Why?
|
Keto Acids | 1 | 2005 | 35 | 0.020 |
Why?
|
Annexins | 1 | 2004 | 38 | 0.020 |
Why?
|
Phospholipases A2 | 1 | 2005 | 197 | 0.010 |
Why?
|
Metabolomics | 1 | 2014 | 1656 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2013 | 2413 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2013 | 6188 | 0.010 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2013 | 1390 | 0.010 |
Why?
|
Hydrocortisone | 2 | 2002 | 1819 | 0.010 |
Why?
|
Cell Line | 1 | 2018 | 15576 | 0.010 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 661 | 0.010 |
Why?
|
Total Lung Capacity | 1 | 2004 | 149 | 0.010 |
Why?
|
Lung Compliance | 1 | 2004 | 200 | 0.010 |
Why?
|
Inhalation | 1 | 2004 | 143 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 2801 | 0.010 |
Why?
|
Interleukin-3 | 1 | 2004 | 425 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2925 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4366 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2010 | 2202 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5835 | 0.010 |
Why?
|
Base Sequence | 1 | 2013 | 12421 | 0.010 |
Why?
|
Computer Simulation | 1 | 2015 | 6233 | 0.010 |
Why?
|
Mutation | 2 | 2022 | 30016 | 0.010 |
Why?
|
Urban Population | 1 | 2010 | 2033 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 2802 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4570 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 1540 | 0.010 |
Why?
|
Algorithms | 2 | 2017 | 14018 | 0.010 |
Why?
|
RNA | 1 | 2011 | 2713 | 0.010 |
Why?
|
Software | 1 | 2015 | 4431 | 0.010 |
Why?
|
Pain | 1 | 2016 | 5061 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2011 | 3769 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2004 | 1146 | 0.010 |
Why?
|
Haplotypes | 1 | 2006 | 2713 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8311 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11069 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 2008 | 10175 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 29868 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2011 | 3045 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 4512 | 0.010 |
Why?
|
Macrophages | 1 | 2013 | 5758 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21337 | 0.010 |
Why?
|
Glycoproteins | 1 | 2005 | 2200 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9476 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9313 | 0.010 |
Why?
|
Depression | 1 | 2016 | 8132 | 0.010 |
Why?
|
Probability | 1 | 2002 | 2475 | 0.010 |
Why?
|
NF-kappa B | 1 | 2004 | 2481 | 0.010 |
Why?
|
Up-Regulation | 1 | 2004 | 4117 | 0.010 |
Why?
|
Patient Readmission | 1 | 2009 | 3269 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 9586 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4919 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2005 | 5463 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2006 | 8516 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2003 | 2044 | 0.010 |
Why?
|
Primary Health Care | 1 | 2007 | 4668 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2009 | 15612 | 0.000 |
Why?
|
Chronic Disease | 1 | 2002 | 9311 | 0.000 |
Why?
|